Apellis Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDApellis Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings growth of 100% provides fundamental context to the price action. However, with RSI at 84, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $40.99 | +0.11% | ABOVE |
| 50 SMA | $33.20 | +23.59% | ABOVE |
| 100 SMA | $27.99 | +46.61% | ABOVE |
| 150 SMA | $26.36 | +55.65% | ABOVE |
| 200 SMA | $26.08 | +57.34% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is APLS in an uptrend right now?
APLS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, APLS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is APLS overbought or oversold?
APLS's RSI (14) is 84. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is APLS outperforming the market?
APLS has a Relative Strength (RS) Rating of 95 out of 99. Yes, APLS is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is APLS in its 52-week range?
APLS is trading at $41.03, which is 100% of its 52-week high ($41.12) and 100% above its 52-week low ($16.83).
How volatile is APLS?
APLS has a Beta of 1.04 and 52-week volatility of 60%. It's more volatile than the S&P 500 - expect bigger swings.